No­vo Nordisk spells out the de­tails be­hind a PhII NASH fail­ure which re­shaped its clin­i­cal plans

A lit­tle more than a year af­ter No­vo Nordisk and Gilead agreed to push in­to big­ger stud­ies of a three-drug com­bo in NASH, the Dan­ish phar­ma has spelled out the da­ta af­ter run­ning in­to a fresh ob­sta­cle on the monother­a­py prospects for their big drug semaglu­tide — brand­ed as Ozem­pic on the mar­ket.

The GLP-1 play­er, which has been rack­ing up im­pres­sive re­sults for di­a­betes and obe­si­ty in beat­ing a path to ma­jor block­buster sta­tus, failed a Phase II tri­al when test­ed against the liv­er dis­ease. We knew that last fall when ex­ecs cit­ed the set­back in their Q3 call. And now we know more of the specifics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER